A detailed history of Aua Capital Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Aua Capital Management, LLC holds 2,709 shares of ABBV stock, worth $487,620. This represents 0.31% of its overall portfolio holdings.

Number of Shares
2,709
Previous 2,813 3.7%
Holding current value
$487,620
Previous $482,000 10.79%
% of portfolio
0.31%
Previous 0.29%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$163.84 - $199.33 $17,039 - $20,730
-104 Reduced 3.7%
2,709 $534,000
Q1 2024

Apr 11, 2024

BUY
$159.82 - $182.1 $16,621 - $18,938
104 Added 3.84%
2,813 $512,000
Q3 2023

Oct 23, 2023

BUY
$133.59 - $154.65 $60,783 - $70,365
455 Added 20.19%
2,709 $403,000
Q2 2023

Jul 11, 2023

SELL
$132.51 - $164.9 $99,382 - $123,675
-750 Reduced 24.97%
2,254 $303,000
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $276 - $331
2 Added 0.07%
3,004 $485,000
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $101,328 - $116,217
-755 Reduced 20.1%
3,002 $403,000
Q1 2022

May 04, 2022

BUY
$131.98 - $163.75 $61,106 - $75,816
463 Added 14.06%
3,757 $609,000
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $23,097 - $29,224
215 Added 6.98%
3,294 $446,000
Q4 2020

Feb 09, 2021

BUY
$80.49 - $108.67 $402 - $543
5 Added 0.16%
3,079 $330,000
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $70,789 - $83,083
824 Added 36.62%
3,074 $269,000
Q2 2020

Jul 13, 2020

SELL
$73.37 - $98.18 $55,834 - $74,714
-761 Reduced 25.27%
2,250 $221,000
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $92 - $123
-1 Reduced 0.03%
3,011 $285,000
Q3 2017

Oct 20, 2017

BUY
$69.85 - $89.22 $210,388 - $268,730
3,012
3,012 $268,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Aua Capital Management, LLC Portfolio

Follow Aua Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aua Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aua Capital Management, LLC with notifications on news.